The diagnosis of neurodegenerative diseases is undergoing fundamental change. Whereas inpatient examinations with MRI, neuropsychological testing, and, above all, invasive lumbar punctures were previously necessary, new ultrasensitive laboratory methods are now opening up much more patient-friendly options. Blood-based Alzheimer’s biomarkers such as neurofilament light chain (NfL) and pTau217 enable reliable diagnosis in outpatient care while reducing risks, stress, and barriers to access for patients.
Priv.-Doz. Dr. Péter Körtvélyessy (MVZ Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Labor Berlin – Charité Vivantes) describes this paradigm shift in detail in his latest article. He explains why minimally invasive blood sampling can change care in the long term, what role new analysis platforms such as SIMOA play, and why cerebrospinal fluid diagnostics remain important despite advances.
Labor Berlin was an early supporter of the development of blood markers and established NfL as a lab-developed test in blood as early as 2020. With a growing portfolio of innovative biomarkers, more precise, safer, and more accessible dementia diagnostics are within reach.
Click here for the full article (p. 18) in Management & Krankenhaus magazine